Alison N Mccormick

7939318, May 10, 2011

Apr 24, 2006

11/410572

Alison A. McCormick - Vacaville CA, US
Mark L. Smith - Davis CA, US
Kenneth E. Palmer - Vacaville CA, US
John A. Lindbo - Vacaville CA, US
Long V. Nguyen - Vacaville CA, US
Gregory P. Pogue - Vacaville CA, US

Kentucky Bioprocessing, LLC - Owensboro KY

C12N 15/63
A61K 35/00

4353201, 424 931

Herein-described are various methods for making a vaccine that are made of re-assembled virus like particles (VLP). First, the VLPs are disassembled into encapsidation intermediate populations. Each encapsidation intermediate population undergoes, for instance, chemical conjugation of unique peptide or nucleic moieties to form separate populations. Thereafter, a predetermined amount of each of the several (one or more) different encapsidation intermediates from the different populations is mixed and joined, forming intact VLPs, surrounding a nucleic acid core, that are composed of different encapsidation intermediate such that the reassembled VLP displays more than one peptide or nucleic acid. The nucleic acid can function either as a scaffold alone or can be engineered for the expression of an immunomodulatory protein in a eukaryotic cell.

20020187952, Dec 12, 2002

Dec 20, 2001

10/038001

Kenneth Palmer - Vacaville CA, US
Gregory Pogue - Vacaville CA, US
Alison McCormick - Vacaville CA, US

A61K048/00
C07H021/04
C12N007/00
C12N015/86

514/044000, 536/023720, 435/235100, 435/456000

A rolling circle DNA replicon which replicates in a host eukaryotic cell and is capable of eliciting an immunization reaction is disclosed. The rolling circle DNA replicon comprises a Rep gene open reading frame placed under transcriptional control of a promoter, which is placed 5′ of the gene. Any sequences that are required to be present in cis on the rolling circle DNA replicon in order that the Rep protein might promote replication of the rolling circle DNA replicon and elicit an immunization reaction are included. At least one expression cassette with an RNA polymerase II promoter, a multiple cloning site, and transcription termination and polyadenylation signals suitable for transcription of RNA molecules not normally intrinsic to a geminiviral, circoviral or nanoviral genome is also included.

20030035807, Feb 20, 2003

Feb 8, 2002

10/067790

Alison McCormick - Vacaville CA, US
Daniel Tuse - Menlo Park CA, US
Stephen Reinl - Sacramento CA, US
John Lindbo - Vacaville CA, US
Thomas Turpen - Vacaville CA, US

A61K039/395
C07K016/30
A01H005/00

424/185100, 800/288000, 530/388100, 424/155100

A polypeptide self-antigen useful in a tumor-specific vaccine mimics one or more epitopes of an antigen uniquely expressed by cells of the tumor. The polypeptide is preferably produced in a plant that has been transformed or transfected with nucleic acid encoding the polypeptide and is obtainable from the plant in correctly folded, preferably soluble form without a need for denaturation and renaturation. This plant-produced polypeptide is immunogenic without a need for exogenous adjuvants or other immunostimulatory materials. The polypeptide is preferably an scFv molecule that bears the idiotype of the surface immunoglobulin of a non-Hodgkin's (or B cell) lymphoma. Upon administration to a subject with lymphoma, the plant-produced, tumor-unique scFv polypeptide induces an idiotype-specific antibody or cell-mediated immune response against the lymphoma.

20030039659, Feb 27, 2003

Feb 8, 2002

10/067892

Alison McCormick - Vacaville CA, US
Daniel Tuse - Menlo Park CA, US
Stephen Reinl - Sacramento CA, US
John Lindbo - Vacaville CA, US
Thomas Turpen - Vacaville CA, US

A61K039/00
C07K014/435
A01H001/00

424/185100, 800/288000, 530/350000

A polypeptide self-antigen useful in a tumor-specific vaccine mimics one or more epitopes of an antigen uniquely expressed by cells of the tumor. The polypeptide is preferably produced in a plant that has been transformed or transfected with nucleic acid encoding the polypeptide and is obtainable from the plant in correctly folded, preferably soluble form without a need for denaturation and renaturation. This plant-produced polypeptide is immunogenic without a need for exogenous adjuvants or other immunostimulatory materials. The polypeptide is preferably an scFv molecule that bears the idiotype of the surface immunoglobulin of a non-Hodgkin's (or B cell) lymphoma. Upon administration to a subject with lymphoma, the plant-produced, tumor-unique scFv polypeptide induces an idiotype-specific antibody or cell-mediated immune response against the lymphoma.

20030044417, Mar 6, 2003

Mar 31, 2000

09/539382

Alison McCormick - Vacaville CA, US
Daniel Tuse - Menlo Park CA, US
Stephen Reinl - Sacramento CA, US
John Lindbo - Vacaville CA, US
Thomas Turpen - Menlo Park CA, US

C12P021/06
C12P021/04
A61K039/395
A61K039/40
A61K039/42
A61K039/00
A61K039/38

424/184100, 424/277100, 424/192100, 424/131100, 424/132100, 424/133100, 435/069100, 435/070100, 435/070210

A polypeptide self-antigen useful in a tumor-specific vaccine mimics one or more epitopes of an antigen uniquely expressed by cells of the tumor. The polypeptide is preferably produced in a plant that has been transformed or transfected with nucleic acid encoding the polypeptide and is obtainable from the plant in correctly folded, preferably soluble form without a need for denaturation and renaturation. This plant-produced polypeptide is immunogenic without a need for exogenous adjuvants or other immunostimulatory materials. The polypeptide is preferably an scFv molecule that bears the idiotype of the surface immunoglobulin of a non-Hodgkin's (or B cell) lymphoma. Upon administration to a subject with lymphoma, the plant-produced, tumor-unique scFv polypeptide induces an idiotype-specific antibody or cell-mediated immune response against the lymphoma.

20030044420, Mar 6, 2003

Feb 8, 2002

10/067893

Alison McCormick - Vacaville CA, US
Daniel Tuse - Menlo Park CA, US
Stephen Reinl - Sacramento CA, US
John Lindbo - Vacaville CA, US
Thomas Turpen - Vacaville CA, US

A61K039/00
C07H021/04
C12P021/02
C12N005/06
C07K014/435
C07K016/28

424/185100, 530/350000, 530/388800, 435/069300, 435/325000, 435/320100, 536/023530

A polypeptide self-antigen useful in a tumor-specific vaccine mimics one or more epitopes of an antigen uniquely expressed by cells of the tumor. The polypeptide is preferably produced in a plant that has been transformed or transfected with nucleic acid encoding the polypeptide and is obtainable from the plant in correctly folded, preferably soluble form without a need for denaturation and renaturation. This plant-produced polypeptide is immunogenic without a need for exogenous adjuvants or other immunostimulatory materials. The polypeptide is preferably an scFv molecule that bears the idiotype of the surface immunoglobulin of a non-Hodgkin's (or B cell) lymphoma. Upon administration to a subject with lymphoma, the plant-produced, tumor-unique scFv polypeptide induces an idiotype-specific antibody or cell-mediated immune response against the lymphoma.

20030124091, Jul 3, 2003

Oct 25, 2002

10/281423

Daniel Tuse - Vacaville CA, US
Thomas Davis - Oak Hill VA, US
Alison McCormick - Vacaville CA, US
Sharon Wannberg - Germantown MD, US

Large Scale Biology Corporation

A61K038/20
A61K038/19
A61K038/18
A61K039/00

424/085100, 424/085200, 424/185100, 514/012000

The present invention relates to human and porcine endothelial cell derived growth factors (EDHF) that contain one or a mixture of more than one endothelial cell proteins having a molecular weight greater than about 30 kDa. The EDHF is added to culture medium to expand tri-lineage pre-dendritic myleomonocytic progenitor cells and culture endothelial cells. The present invention also relates to a method of amplifying myeloid dendritic cell precursors both in vitro and in vivo. The EDHF is also used therapeutically to increase myeloid dendritic cell production in vivo to enhance the activity of vaccines.

20040033585, Feb 19, 2004

Jun 6, 2003

10/457082

Alison McCormick - Vacaville CA, US
Mark Smith - Davis CA, US
Kenneth Palmer - Vacaville CA, US
John Lindbo - Vacaville CA, US
Long Nguyen - Vacaville CA, US
Gregory Pogue - Vacaville CA, US

C12N015/86
C12N007/00

435/235100, 435/456000

Herein described are various methods for making a vaccine that are made of re-assembled virus like particles (VLP). First, the VLPs are disassembled into encapsidation intermediate populations. Each encapsidation intermediate population undergoes, for instance, chemical conjugation of unique peptide or nucleic moieties to form separate populations. Thereafter, a predetermined amount of each of the several (one or more) different encapsidation intermediates from the different populations is mixed and joined, forming intact VLPs, surrounding a nucleic acid core, that are composed of different encapsidation intermediate such that the reassembled VLP displays more than one peptide or nucleic acid. The nucleic acid can function either as a scaffold alone or can be engineered for the expression of an immunomodulatory protein in a eukaryotic cell.